MOH (Palestine)

Palestine MoH (Wizārat al-Siḥḥa al-Filasṭīniyya) — operating through the Pharmaceutical General Administration (PGA) + Central Public Health Laboratory (CPHL) + Palestinian National Pharmacovigilance Centre — is the State of Palestine's national regulatory authority for human medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + dietary supplements + pharmacy practice + controlled substances across the West Bank + East Jerusalem + Gaza Strip. Palestine MoH operates under the Palestinian Public Health Law 20 of 2004 + Pharmacy Practice Law 21 of 2017 + Drug Registration Decision 1 of 2013 + Narcotics + Psychotropics Law 7 of 1955 (amended) + Council of Ministers Decisions + PGA Decisions + Guidance Documents.

Palestine MoH organisational structure includes:

• Minister of Health — political head appointed by the Palestinian Authority Council of Ministers.
• Deputy Minister + Director General + Undersecretary for Pharmaceutical Affairs.
• Pharmaceutical General Administration (PGA) — central pharmaceutical regulatory body.
• Drug Registration Department — drug + biological + vaccine + biosimilar + generic-medicine registration.
• Pharmaceutical Inspection Department — GMP + GDP + GPP + GVP + GLP inspections of Palestinian + foreign manufacturing facilities.
• Medical Devices Department — medical-device + IVD registration + matériovigilance.
• Pharmacy Practice Department — pharmacy + pharmaceutical-establishment licensing.
• Cosmetics + Dietary Supplements Department — cosmetic-product + dietary-supplement notification.
• Controlled Substances Department — narcotics + psychotropics framework coordination with INCB + Ministry of Interior + Palestinian Civil Police + parallel Gaza authorities.
• Central Public Health Laboratory (CPHL) — central pharmaceutical + public-health QC laboratory in Ramallah; capacity expansion via WHO + EU + bilateral-donor support.
• Palestinian National Pharmacovigilance Centre — WHO PIDM-affiliated national PV centre coordinated by Palestine MoH PGA.
• International Affairs Section — WHO + Arab League + EMRO + UNRWA + UN-agency coordination.

Palestine's distinctive West Bank-Gaza administrative-split context: since the 2007 Hamas-Fatah split, Gaza MoH has operated semi-independently under Hamas de facto authority, with parallel pharmaceutical-regulatory engagement. The Palestinian Authority MoH in Ramallah retains internationally-recognised legitimacy + maintains substantial pharmaceutical-procurement coordination for both West Bank + Gaza (through the Ministry of Health Central Drug Stores), but Gaza-based pharmacies + hospitals + healthcare operators often engage with parallel Gaza MoH structures for licensing + day-to-day operations. This administrative-split duality + Israeli-occupation operational context — particularly substantial Israeli import-licensing + customs + checkpoint controls under the Paris Protocol (1994 economic annex to the Oslo Accords) restricting independent Palestinian importation; Israeli-controlled Allenby Bridge crossing for Jordan-to-West-Bank pharmaceutical imports; Israeli/Egyptian-controlled Rafah + Kerem Shalom crossings for Egypt-to-Gaza pharmaceutical imports; substantial Israeli MoH + Israeli Pharmacist Association indirect regulatory influence through the Paris Protocol customs union — are among the most operationally significant features of Palestinian pharmaceutical market access.

Palestine MoH is distinct from + complementary to: the Palestinian Pharmacists Syndicate (professional licensing body for individual pharmacists); the historical ~7+ Palestinian-domestic pharmaceutical-manufacturing industry (Jerusalem Pharmaceuticals + Birzeit Pharmaceuticals + Beit Jala Pharmaceutical Company + Pharmacare + Dar Al Shifa Pharmaceuticals + Megapharm + Jepharm) covering substantial domestic essential-medicines + generics consumption + substantial Arab + EMRO export presence; Palestinian medical schools + pharmacy faculties (Al-Quds University + An-Najah National University + Birzeit University + Palestine Polytechnic University + Islamic University of Gaza + Al-Azhar University Gaza); UNRWA's parallel pharmaceutical-procurement + ~140 primary-healthcare-centre network for Palestine refugees across the West Bank + Gaza + Jordan + Lebanon + Syria; and substantial UN-agency + NGO humanitarian healthcare operators including WHO + UNICEF + UNFPA + UNDP + ICRC + MSF + Palestine Red Crescent Society + Medical Aid for Palestinians + Premiere Urgence Internationale supporting substantial humanitarian-healthcare programmes particularly during recurrent Gaza humanitarian-emergency contexts.

Palestine MoH is an active League of Arab States Council of Arab Ministers of Health participant + a WHO Eastern Mediterranean Regional Office (EMRO) participant + a WHO PIDM member + maintains substantial bilateral cooperation with Jordanian JFDA (closest peer regulator + substantial pharmaceutical-import source via Allenby Bridge logistics route) + Egyptian EDA (substantial pharmaceutical-import source via Rafah crossing logistics for Gaza) + EU MoHs (substantial EU donor cooperation for Palestinian healthcare-system support) + Turkish TİTCK + Indian CDSCO (substantial pharmaceutical-trade ties) reflecting Palestine's pharmaceutical-trade relationships.

Palestinian pharmaceutical regulation operates under a layered framework of Laws + Council of Ministers Decisions + PGA Decisions + Guidance Documents — with distinctive West Bank-Gaza administrative-split + Israeli-occupation Paris Protocol customs-union operational implications:

• Public Health Law 20 of 2004 — primary pharmaceutical-regulatory framework.
• Pharmacy Practice Law 21 of 2017 — updated pharmacy practice + pharmaceutical-establishments framework.
• Drug Registration Decision 1 of 2013 — PGA Drug Registration procedural framework.
• Narcotics + Psychotropics Law 7 of 1955 (amended) — controlled substances framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988.
• Council of Ministers Decisions + PGA Decisions on Drug Registration + Medical Devices + Cosmetics + Dietary Supplements + Pricing + Pharmacy Practice.
• Palestine MoH GMP Guide — substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2.
• Palestine MoH GDP Guide — substantively aligned with WHO + EU GDP.
• Palestine MoH GCP Guide — substantively aligned with ICH E6(R2).
• Palestine MoH GVP Guide — substantively aligned with ICH E2 + EU GVP.
• Pharmacopoeia recognition — recognises British Pharmacopoeia + USP + European Pharmacopoeia + Indian Pharmacopoeia + Arab Pharmacopoeia + Jordanian Pharmacopoeia.
• Palestinian National Essential Medicines List — substantively aligned with WHO Essential Medicines List + reflecting UNRWA + UN-agency humanitarian procurement substantial role.
• Palestine MoH Medical Devices framework — Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF.
• Palestine MoH Cosmetics framework — substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation.
• Palestine MoH Variations + 5-year Drug Registration Renewal framework.
• Paris Protocol Customs Union Framework — distinctive Israeli-customs operational implication; Israeli MoH approval + import-licensing required for substantial pharmaceutical imports through Israeli ports (Ashdod + Haifa); restricts independent Palestinian importation pathways.
• West Bank-Gaza Administrative-Split Framework — Palestinian Authority MoH in Ramallah retains internationally-recognised legitimacy but Gaza-based operators frequently engage with parallel Gaza MoH structures.
• UNRWA + UN-Agency Humanitarian Procurement Framework — substantial parallel framework for Palestine refugee + vulnerable-population healthcare via UNRWA ~140 primary-healthcare-centre network + WHO + UNICEF + UNFPA + UNDP + ICRC humanitarian-imported medicines + devices.

The Central Public Health Laboratory (CPHL) in Ramallah is Palestine MoH's central pharmaceutical + public-health quality-control laboratory + has been expanding capacity via WHO + EU + bilateral-donor support. Palestine MoH GMP Inspection Department conducts inspections of Palestinian + foreign manufacturing facilities, with substantial operational complexity from Israeli-occupation context restricting foreign-inspector access to Palestinian territories + Palestinian-inspector access to foreign manufacturing facilities.

• ISO/IEC 17025 — CPHL pursuing ISO/IEC 17025 scope expansion via WHO + EU + bilateral-donor capacity-building support.
• WHO PQ-Lab Aspiration — CPHL pursuing WHO PQ-Lab dialogue as long-term aspiration.
• Vaccine lot release — CPHL conducts vaccine lot-release testing for Palestine MoH + Palestinian Expanded Programme on Immunization including substantial UNICEF + WHO + Gavi-supported vaccine procurement.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + post-market surveillance + targeted enforcement testing.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Cosmetic-product + dietary-supplement testing — safety + ingredient compliance testing.
• Counterfeit-medicine forensics — forensic analytical support for Palestine MoH + Palestinian Civil Police + WHO Global Surveillance & Monitoring System contributions; substantial counterfeit-medicine quality risks given occupation-context supply-chain complexity + cross-border smuggling via tunnel economies (historically Gaza-Egypt).
• UNRWA + UN-Agency Humanitarian Quality Verification — substantial parallel humanitarian quality-verification framework operated by UNRWA + WHO + UNICEF procurement + quality-assurance teams given Palestine's substantial UN-agency humanitarian-procurement role.
• Capacity-building — substantial WHO + EU + USP + bilateral-donor capacity-building programmes + training for Palestinian pharmaceutical analysts + CPHL capacity expansion.
• GMP Inspectorate support — provides scientific + technical support for Palestine MoH Pharmaceutical Inspection Department GMP inspections; substantial operational complexity for foreign-manufacturing inspections given occupation-context inspector-mobility constraints.
• Palestinian domestic manufacturer support — supports ~7+ Palestinian-domestic manufacturers (Jerusalem Pharmaceuticals + Birzeit Pharmaceuticals + Beit Jala + Pharmacare + Dar Al Shifa + Megapharm + Jepharm) covering substantial domestic essential-medicines + generics + Arab + EMRO export.
• Gaza humanitarian medicine quality — distinctive substantial role for Gaza-context humanitarian-procured medicines during recurrent Gaza humanitarian-emergency contexts.

Palestine MoH medical-device + IVD regulation operates under Palestine MoH Medical Devices framework with Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF. Foreign manufacturers must appoint a Palestinian Authorised Representative. Palestine's medical-device market is dominated by foreign manufacturers + substantial UNRWA + UN-agency + NGO humanitarian-imported devices.

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR + GHTF/IMDRF; IVDs classified under separate framework.
• Palestinian Authorised Representative — Palestine-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + Palestine MoH regulatory interface.
• ISO 13485:2016 — recognised by Palestine MoH as QMS evidence framework.
• Reliance pathways — Palestine MoH accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence; CE Mark + FDA particularly central.
• Arab League Medical Devices Harmonisation — Palestine participates in Council of Arab Ministers of Health medical-device harmonisation.
• UNRWA + UN-Agency Medical Device Humanitarian Importation — substantial framework given UNRWA + WHO + UNICEF + UNHCR + UNFPA + ICRC + NGO humanitarian medical-device + IVD importation.
• Paris Protocol Israeli-customs Operational Implication — Israeli MoH approval + import-licensing required for substantial medical-device imports through Israeli ports (Ashdod + Haifa) under Paris Protocol customs union; substantial operational complexity.
• West Bank / Gaza Parallel Medical Device Procurement — distinctive parallel Ramallah-based Palestinian Authority + Gaza-based parallel structures reflecting administrative-split reality.
• Post-market vigilance — Palestine MoH operates medical-device adverse-event reporting; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• IVD Réactovigilance — Palestine MoH operates IVD réactovigilance reflecting Palestine's clinical-laboratory infrastructure including teaching hospitals + UN-agency-supported field laboratories.
• Cosmetic Notification — cosmetics require Palestine MoH Cosmetic Notification + Arabic labelling; INCI-aligned ingredient listing + safety substantiation; substantively EU-aligned framework.
• Dietary Supplement Registration — Palestine MoH Dietary Supplements framework; substantively aligned with EU food-supplement framework + Codex Alimentarius.
• Importation Permit — Palestine MoH Importation Permit required in addition to product registration; coordination with Israeli + Egyptian + Palestinian customs.

Palestine MoH operates the Palestinian National Pharmacovigilance Centre. Palestine is a WHO Programme for International Drug Monitoring (PIDM) member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The Palestinian National Pharmacovigilance Centre coordinates with university teaching hospitals + UNRWA + UN-agency + NGO humanitarian-healthcare operators. Palestine's pharmacovigilance is uniquely shaped by occupation-context healthcare-access constraints + substantial Palestine refugee + vulnerable-population vaccine + essential-medicines safety surveillance commitments + recurrent Gaza humanitarian-emergency response + substantial counterfeit + substandard medicine surveillance commitments.

• Palestinian National Pharmacovigilance Centre — coordinated by Palestine MoH PGA.
• WHO PIDM Member — Palestine contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Palestinian PV Network — coordinated national network with effector centres in major Palestinian university teaching hospitals (Al-Makassed Hospital — East Jerusalem, Augusta Victoria Hospital — East Jerusalem, Palestinian Medical Complex — Ramallah, An-Najah National University Hospital — Nablus, European Gaza Hospital, Al-Shifa Hospital — Gaza, Al-Aqsa Martyrs Hospital — Gaza, Nasser Hospital — Khan Younis) + UNRWA primary-healthcare centres + Marketing Authorisation Holders + UN-agency humanitarian healthcare operators.
• ADR Reporting — Palestine MoH operates ADR reporting via Palestine MoH portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — Palestine MoH accepts E2B(R3) format ICSR submissions; 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2).
• Risk Management Plans (RMP) — Palestine MoH requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• AEFI Surveillance — Palestinian vaccine adverse-event surveillance aligned with WHO methodology; central to Palestinian Expanded Programme on Immunization + substantial UNICEF + UNRWA + Gavi + WHO-supported immunisation campaigns.
• UNRWA Palestine Refugee PV — distinctive substantial commitments for Palestine refugee + vulnerable-population vaccine + essential-medicines safety surveillance coordinated with UNRWA across West Bank + Gaza + Jordan + Lebanon + Syria.
• Gaza humanitarian-emergency response — distinctive substantial role given recurrent Gaza humanitarian-emergency contexts; substantial WHO + UNICEF + MSF + ICRC + Medical Aid for Palestinians + Palestine Red Crescent outbreak-response coordination.
• Matériovigilance + Cosmétovigilance — Palestine MoH operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
• Counterfeit + substandard medicine surveillance — distinctive substantial role given occupation-context supply-chain complexity + cross-border smuggling + tunnel-economy (historically Gaza-Egypt) counterfeit risks.
• Arab League Pharmacovigilance — Palestine participates in Arab League Council of Arab Ministers of Health pharmacovigilance harmonisation.

• WHO EMRO Participant — Palestine MoH is an active WHO Eastern Mediterranean Regional Office participant; substantial WHO humanitarian healthcare cooperation.
• WHO PIDM Member — Palestine contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Arab League Council of Arab Ministers of Health Participant — alongside Egyptian EDA + Jordanian JFDA + Saudi SFDA + UAE MoHAP + Lebanese MoPH + Iraq MoH + Syria MoH + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH + Yemen SBDMA.
• Jordanian JFDA Bilateral — closest peer regulator + substantial pharmaceutical-trade cooperation via Allenby Bridge logistics route + substantial Palestinian refugee context overlap.
• Egyptian EDA Bilateral — substantial pharmaceutical-trade cooperation via Rafah crossing logistics for Gaza + Arab League co-leader.
• EMA + ANSM + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS Bilateral — Palestine MoH maintains substantial Stringent Regulatory Authority reliance practice.
• Indian CDSCO Bilateral — substantial trade-driven cooperation reflecting India as substantial pharmaceutical import source for Palestine.
• Turkish TİTCK Bilateral — substantial trade-driven cooperation reflecting Türkiye's substantial pharmaceutical export trade with Palestine.
• EU Cooperation — substantial EU donor cooperation for Palestinian healthcare-system support including PEGASE + Joint Financing Arrangement + UNRWA support + Pharmaceutical Sector Strategy support.
• PIC/S Cooperation — Palestine MoH GMP Guide substantively aligned with PIC/S GMP + EU GMP + ICH Q7.
• ICH Observer Practice — ICH guidelines implemented in Palestinian regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• ICDRA + EMRO participation — historical International Conference of Drug Regulatory Authorities + active WHO EMRO participant.
• UNRWA + UN-Agency Humanitarian Cooperation — substantial cooperation with UNRWA (~140 primary-healthcare centres across West Bank + Gaza + Jordan + Lebanon + Syria) + WHO + UNICEF + UNFPA + UNDP + ICRC + MSF + Palestine Red Crescent Society + Medical Aid for Palestinians + Premiere Urgence Internationale.
• Donor Cooperation — substantial bilateral cooperation with EU + USAID (historical) + UK FCDO + Germany BMZ/GIZ + Japan JICA + Norway + Sweden + Switzerland + World Bank + Islamic Development Bank for healthcare + reconstruction programming.
• Israeli MoH Indirect Coordination — distinctive operational coordination via Paris Protocol customs-union framework for substantial pharmaceutical-import logistics through Israeli ports + checkpoints.

• West Bank-Gaza administrative-split parallel-registration strategy missed — most operationally significant feature of Palestinian pharmaceutical market access frequently overlooked; foreign manufacturers + UN-agency humanitarian operators targeting all-of-Palestine may need to navigate parallel Ramallah-based Palestinian Authority + Gaza-based parallel engagement with differing operational timelines + administrative procedures.
• Paris Protocol Israeli-customs operational complexity not understood — substantial Israeli MoH approval + import-licensing + customs + checkpoint controls under Paris Protocol customs union for pharmaceutical imports through Israeli ports (Ashdod + Haifa); substantial operational complexity + delays + cost implications frequently underestimated.
• Palestinian Authorised Representative not properly designated — application rejected at PGA intake or post-approval compliance failure; Palestinian Authorised Representative must be Palestine-resident legal entity with appropriate licensure.
• Arabic labelling deficiencies — Arabic required; English overlay common for hospital + specialty products; many applicants provide insufficient Arabic-language patient leaflet content.
• Palestine MoH GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Palestine-specific clarifications.
• Palestine climate-zone stability data missing — Palestine is Climate Zone II coastal (Gaza + coastal Israel-occupied corridors) + IVa interior (West Bank + Jordan Valley); requires zonal-specific stability data including humidity + temperature considerations.
• WHO PQ reliance under-utilised — WHO-PQ-approved products eligible for accelerated PGA review (90-120 day target); substantially under-utilised by many applicants despite Palestine's UN-agency humanitarian-procurement role.
• Jordanian JFDA / Egyptian EDA reliance under-utilised — JFDA + EDA are closest peer regulators + reliance pathways substantially reduce timeline.
• UNRWA + UN-Agency humanitarian procurement pathway not leveraged — substantial UNRWA + WHO + UNICEF + UNFPA + UNDP + ICRC opportunity for Palestine refugee + vulnerable-population healthcare frequently overlooked.
• Gaza humanitarian-emergency response opportunity not leveraged — recurrent Gaza humanitarian-emergency context creates substantial WHO + UNICEF + MSF + ICRC + Medical Aid for Palestinians + Palestine Red Crescent outbreak-response procurement opportunity.
• EMA + SRA reliance under-utilised — Palestine MoH operates substantial reliance on EMA + Stringent Regulatory Authority decisions.
• Arab League harmonisation not leveraged — Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised.
• Trade-partner reliance (India CDSCO / Türkiye TİTCK) under-utilised — substantial trade-driven reliance reflecting Palestine's pharmaceutical-import trade relationships.
• Bioequivalence centres + biowaiver — Palestine MoH BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
• Essential Medicines + Vital Medicines accelerated pathway not leveraged — accelerated Registration under-utilised; 90-120 calendar day target.
• Counterfeit + substandard medicine quality risks under-monitored — occupation-context supply-chain complexity + cross-border smuggling + tunnel economies (historically Gaza-Egypt) create substantial counterfeit + substandard medicine quality risks requiring substantial post-market quality surveillance.
• Variations strategy not planned — variations procedure substantively similar to EU but with Palestine-specific timelines + fee structure + occupation-context administrative delays.
• Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.

V5 Ultimate provides the operational infrastructure Palestinian + foreign-supplier sites + UN-agency humanitarian operators + UNRWA need for Law 20 of 2004 + Law 21 of 2017 + Decision 1 of 2013 + Palestine MoH GMP + Medical Devices framework + WHO PQ + EMA + SRA reliance + Arab League + Jordanian JFDA + Egyptian EDA + Indian CDSCO + Turkish TİTCK trade-partner reliance + Palestinian National Pharmacovigilance Centre + UNRWA + UN-agency humanitarian procurement + Paris Protocol Israeli-customs operational coordination + West Bank-Gaza administrative-split parallel engagement.

• Palestine MoH GMP control framework — PIC/S + EU GMP + ICH Q7 + WHO TRS 986 Annex 2-aligned controls with ALCOA+ data-integrity + Palestine-specific clarifications + Climate Zone II coastal + IVa interior stability monitoring.
• Palestine MoH Registration dossier packaging — Palestine CTD-aligned dossier structure with Palestine Module 1 specifics + Module 3 stability + Arabic patient leaflet + English overlay + Palestinian Authorised Representative declarations + Law 20 of 2004 framework.
• West Bank / Gaza parallel Registration workflow — parallel Ramallah-based Palestinian Authority + Gaza-based parallel structures packaging reflecting administrative-split reality.
• Paris Protocol Israeli-customs operational workflow — distinctive Israeli MoH approval + import-licensing + customs + checkpoint coordination packaging via Ashdod + Haifa ports + Allenby Bridge + Erez + Kerem Shalom checkpoints.
• WHO PQ reliance workflow — WHO-PQ-approved product packaging with reduced dossier + accelerated PGA review (90-120 day target).
• EMA + SRA reliance workflow — Palestine MoH-EMA + Palestine MoH-FDA + Palestine MoH-Health Canada + TGA + Swissmedic + MHRA + MFDS reliance packaging.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging.
• Jordanian JFDA + Egyptian EDA reliance workflow — closest peer regulator reliance packaging via Allenby Bridge + Rafah crossing logistics routes.
• Trade-partner reliance workflow (India CDSCO / Türkiye TİTCK) — substantial trade-driven reliance packaging reflecting Palestine's pharmaceutical-import trade relationships.
• UNRWA + UN-Agency humanitarian procurement workflow — UNRWA ~140 primary-healthcare-centre network + WHO + UNICEF + UNFPA + UNDP + ICRC procurement framework packaging.
• Gaza humanitarian-emergency response workflow — WHO + UNICEF + MSF + ICRC + Medical Aid for Palestinians + Palestine Red Crescent outbreak-response procurement framework packaging.
• Palestinian Authorised Representative workflow — foreign-manufacturer Palestinian Authorised Representative designation + role-management + Palestine-specific post-market surveillance.
• Palestinian clinical-trial workflow — Palestine MoH CTA + Al-Quds / An-Najah / Birzeit / Islamic University of Gaza IRB coordination + Palestinian SUSAR reporting via Palestinian National Pharmacovigilance Centre.
• Palestinian National PV Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Arabic ICSR + Palestinian PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + UNRWA Palestine refugee safety surveillance.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging.
• Medical-device + IVD + cosmetic + dietary-supplement workflow — Palestine MoH frameworks dossier packaging + Class I-III classification + ISO 13485 + Authorised Representative + post-market vigilance.
• Counterfeit + substandard medicine surveillance workflow — Palestine's occupation-context supply-chain complexity + cross-border smuggling monitoring + WHO Global Surveillance & Monitoring System integration.
• Essential Medicines + Vital Medicines accelerated workflow — Palestinian National Essential Medicines List + WHO Essential Medicines List + public-health emergency product packaging.
• Arab League + Mashreq + trade-partner regional bridging — for companies operating across Arab League + Mashreq + Jordanian + Egyptian + Indian + Turkish trade-partner jurisdictions, V5 surfaces Palestine MoH + Jordan JFDA + Egypt EDA + Lebanon MoPH + Syria MoH + India CDSCO + Türkiye TİTCK harmonised dossier-element reuse alongside national-specific extensions.